VPTDF (VentriPoint Diagnostics) 3-Year Share Buyback Ratio: -2.60% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPTDF VentriPoint Diagnostics Ltd VPTDF
11 GF Score
Price $0.07
! 4 Warning Signs
View Full Analysis

What is VentriPoint Diagnostics 3-Year Share Buyback Ratio?

VentriPoint Diagnostics VPTDF -6.08% 11 3-Year Share Buyback Ratio is -2.60 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 614 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 50.33% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. VentriPoint Diagnostics's current 3-Year Share Buyback Ratio was -2.60%.

The historical rank and industry rank for VentriPoint Diagnostics's 3-Year Share Buyback Ratio or its related term are showing as below:

VPTDF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -61.4   Med: -30.1   Max: -1.4
Current: -2.6

During the past 13 years, VentriPoint Diagnostics's highest 3-Year Share Buyback Ratio was -1.40%. The lowest was -61.40%. And the median was -30.10%.

VPTDF's 3-Year Share Buyback Ratio is ranked better than
50.33% of 614 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs VPTDF: -2.60

VentriPoint Diagnostics (OTCPK:VPTDF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


VentriPoint Diagnostics 3-Year Share Buyback Ratio Related Terms


VPTDF vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison

For the Medical Devices subindustry, VentriPoint Diagnostics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's 3-Year Share Buyback Ratio falls into.


VPTDF
11GF Score
VentriPoint Diagnostics Ltd VPTDF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VentriPoint Diagnostics 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -2.60 mean?
VentriPoint Diagnostics (VPTDF) has a 3-Year Share Buyback Ratio of -2.60 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #305 out of 614 companies in the Medical Devices & Instruments industry, placing it in the top 49.7%.
Is VentriPoint Diagnostics' 3-Year Share Buyback Ratio too high?
VentriPoint Diagnostics' current 3-Year Share Buyback Ratio is -2.60. Based on the distribution chart, VentriPoint Diagnostics ranks #305 out of 614 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, VentriPoint Diagnostics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #305 out of 614 companies for 3-Year Share Buyback Ratio. This puts VentriPoint Diagnostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current 3-Year Share Buyback Ratio is -2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current 3-Year Share Buyback Ratio of -2.60. The current 3-Year Share Buyback Ratio is -2.60. VentriPoint Diagnostics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current 3-Year Share Buyback Ratio is -2.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
11GF Score

Get the complete analysis for VPTDF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price